Anticholinergics were used in tolterodine 1, 2 mg and propiverine 10, 20 mg. Combination therapy significantly improved IPSS storage subscores, urgency, and QoL, compared with alpha-blocker monotherapy. There was no difference among combination therapy groups according to the kind and dosage of the drug.40 Efficacy and safety of low-dose propiverine in male LUTS patients with storage symptoms was studied in a prospective, randomized, single-blinded and multicenter clinical trial.41 Two hundred and nine men with LUTS/BPH with storage symptoms (IPSS score ≥12; storage symptoms ≥4) were randomly assigned to either the control group (alfuzosin

10 mg, once daily) or the combined group (alfuzosin 10 mg, once daily, and propiverine 10 mg, once daily) for 2 months. IPSS, Qmax, and PVR were used to grade symptoms, side-effects, and impact on QoL. In the combined group, IPSS total score and IPSS storage symptom score were significantly selleck products improved compared with the control group. The IPSS voiding symptom score, QoL, Qmax, and PVR did not differ

significantly. There were no serious side-effects in either group. In our study of propiverine 20 mg combination therapy,20 the incidence of dry mouth was 18.3%, but only 1.5% in this study. However, this study has several weak points. It is a Acalabrutinib datasheet prospective and multicenter, but open-label, single-blinded. And the follow-up period was only 8 weeks, which is shorter than in usual studies. The Qmax was not considered as an inclusion criterion and the mean prostate size was small. In addition the primary endpoint was only whether storage Carnitine palmitoyltransferase II symptoms of the IPSS improved. Recently Nishizawa et al.42 reported a randomized, controlled trial to evaluate the efficacy and safety of combination therapy of tamsulosin with propiverine in men with both BPH and OAB (TAABO study).

Men 50 years or older who had an IPSS of 8 or higher, an urgency item score of 1 or higher, and QOL score of 2 or higher were enrolled. After 8 weeks of tamsulosin 0.2 mg/day, patients who met the inclusion criteria (eight micturitions per 24 h and one urgency episode per 24 h, evaluated by bladder diary) were eligible for 12 weeks of continued Treatment II. Five hundred and fifteen patients were enrolled. Thereafter, 214 patients were assigned randomly to receive either tamsulosin alone (n = 67), tamsulosin plus propiverine 10 mg (n = 72), or tamsulosin plus propiverine 20 mg (n = 75) in Treatment II. The primary efficacy endpoint was a change in micturitions per 24 h documented in the bladder diary. The change from baseline in urgency episodes per 24 h, IPSS, IPSS/QOL subscore, urinary flow rate and PVR were assessed as secondary efficacy measures. A total of 141 men (47 tamsulosin, 49 tamsulosin plus propiverine 10 mg, and 45 tamsulosin plus propiverine 20 mg patients) were assessed by week 12.